摘要
目的:探讨卵巢肿瘤患者血浆溶血磷脂酸(LPA)水平及其受体Edg-2/Edg-7在卵巢肿瘤组织中的表达情况。方法:测定卵巢恶性肿瘤57例、良性肿瘤66例及健康对照37例血浆LPA水平,并用RT-PCR方法检测其中正常卵巢组织16例、卵巢恶性肿瘤24例及卵巢良性肿瘤组织32例Edg-2/Edg-7mRNA的表达情况。结果:卵巢恶性肿瘤,良性肿瘤及健康对照者血浆LPA水平分别为(5.63±2.35)μmol/L、(2.80±1.13)μmol/L(、2.51±1.08)μmol/L,前者血浆LPA水平与后两者相比,差异有统计学意义(P<0.01);后两者之间血浆LPA水平差异无统计学意义(P>0.05)。Edg-7的表达水平恶性肿瘤组织高于良性及正常卵巢组织(P<0.01);Edg-2的表达卵巢低于后两者(P<0.01)。结论:血浆LPA及其受体Edg-2/Edg-7可能成为治疗卵巢恶性肿瘤的新靶点。
Objective ：To investigate the levels of lysophosphatidic acid （LPA） present in plasma and the expression of LPA receptor Edg-2/in tumor from patients with ovarian tumor. Methods： A research assay was used to measure LPA levels in plasma from 57 patients with ovarian carcinoma,66 patients with ovarian benign disease and 37 healthy control women in the Clinical Medical College of Yangzhou University from January 2002 to January 2004 . The RT-PCR was used to determine the mRNA expression of Edg-2/Edg-7 in ovary of 16 healthy control women ,24 patients with ovarian carcinoma and 32 patients with ovarian benign disease. Result：Patients in ovarian carcinoma group had significantly higher plasma LPA levels （5.63±2.35）μmol/L compared with the ovarian benign disease group （2.80±1.13）μmol/L （P〈0.01）, and healthy control group （2.51±1.08）μmol/L （P〈0.01）..There were no statistically significant differences in plasma LPA levels between patients with ovarian benign disease and healthy control women （P〉0.05）. The mRNA expression of Edg-7 in the ovarian carcinoma group was higher than that in normal ovarian and ovarian benign diseases（P〈0.01）, while there was lower mRNA expression of Edg- 2 in the ovarian carcinoma group than that in the normal ovarian and ovarian benign diseases （P〈0.01）. Conclusion：Plasma LPA levels of patients with ovarian carcinoma were significantly higher than those of patients with ovarian benign disease and healthy control. The expression of Edg-7 were detected in several ovarian carcinoma and Edg-2 expressed in most of normal ovarian and ovarian benign disease. Plasma LPA and its Edg-2/Edg-7 receptor might be therapeutic targets for treating ovarian malignant tumor.
出处
《南通大学学报（医学版）》
2006年第6期432-434,437,共4页
Journal of Nantong University(Medical sciences)
